A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy
Phase of Trial: Phase I/II
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Venetoclax (Primary) ; Cobimetinib; Idasanutlin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 01 Nov 2017 According to a Genentech media release, data from the study will be presented at the American Society of Hematology (ASH) 2017 Annual Meeting.
- 26 Oct 2017 Planned End Date changed from 31 Jul 2019 to 15 Jan 2020.
- 26 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 15 Jan 2020.